Day: February 3, 2026

FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)        Name of exempt principal trader: Investec Bank plc(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree CAB Payments Holdings Plc        (c)        Name of the party to the offer with which exempt principal trader is connected: Investec is Joint Broker to CAB Payments Holdings Plc(d)        Date dealing undertaken: 02nd February 2026(e)        In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?         If it is a cash offer...

INAUGURAL BROAD ARROW GLOBAL ICONS: ONLINE AUCTION ACHIEVES €18.3 MILLION IN TOTAL SALES WITH A SELL-THROUGH RATE OF 90 PERCENT | FIRST EVER PUBLIC SALE OF MICHAEL SCHUMACHER’S HISTORIC 1992 BENETTON B192 FORMULA ONE CAR BRINGS €5.082.000 | 1971 LAMBORGHINI MIURA P400 S SELLS FOR €1.716.000 AND EXCITING BIDDING BATTLE SEES A 2003 FERRARI 360 CHALLENGE STRADALE ACHIEVE A EUROPEAN RECORD OF €561.000 | RARE FERRARI 550 BARCHETTA PININFARINA SELLS IN GLOBAL ICONS: UK ONLINE FOR £335,500 | REPLICA OF AYRTON SENNA’S 1988 MCLAREN HELMET SELLS IN GLOBAL ICONS: MEMORABILIA ONLINE AUCTION FOR INCREDIBLE €55.625The top seller of Broad Arrow’s Global Icons Online Auction Series, an ex-Michael Schumacher 1992 Benetton B192-05, pictured at Broad Arrow’s live preview event at the iconic Roland-Garros Stadium in Paris.Credit – Federico...

Today, Koninklijke KPN N.V. (“KPN”) announces its intention to issue a EUR 500m (expected) size Eurobond under its Global Medium Term Note programme. The proceeds from the new bond offering will be used to refinance existing indebtedness and for general corporate purposes. Simultaneously, KPN announces an offer to repurchase any and all of its GBP 400m 5.00% notes due 2026 (ISIN: XS0707430947) of which GBP 250m is outstanding and up to GBP 300m of its GBP 850m 5.75% notes due 2029 (ISIN: XS0451790280) of which GBP 550m is outstanding (the “Offers”). Terms of the Offers are set out in the Tender Offer Memorandum dated 3 February 2026, which can be obtained from the Tender Agent. The purpose of this transaction is to proactively manage KPN’s debt structure and reduce near term refinancing requirements. KPN’s obligation to accept notes tendered...

Vancouver, British Columbia, Feb. 03, 2026 (GLOBE NEWSWIRE) — NEW EARTH RESOURCES CORP. (CSE: EATH) (“New Earth” or the “Company”) is pleased to announce the appointment of Jack Lifton as an advisor to the Company. Mr. Lifton is a globally recognized consultant in the natural resources sector, bringing decades of experience across mining, refining, fabrication, and the manufacturing of specialty chemicals and technology metals. He has held senior roles including research scientist, technical operations manager, plant manager, and CEO in the OEM automotive electronics and rare metals industries. He is widely known for his expertise in innovative processing technologies for Rare Earth Elements (REEs) and other critical metals. Currently, Mr. Lifton serves as Co-Chair of the Critical Minerals Institute (CMI), focused on developing...

LEADING EDGE MATERIALS’ PROGRESS UPDATE ON ROMANIAN EXPLORATION PROJECT2025 exploration campaign identifies significant areas of mineralisation underground in Valea Leucii, Dibarz and Avram Iancu, and wider potential across the exploration licence. Underground development mapping and sampling data reveal extensive mineralisation. Potential exists for mineralisation between Valea Leucii, Dibarz, and Avram Iancu to be connected, giving a mineralised zone extending approximately 6 kilometres north–south and a similar distance east–west.Vancouver, 2 February 2026 – Leading Edge Materials Corp. (“Leading Edge Materials” or the “Company”) (TSXV: LEM) (Nasdaq First North: LEMSE) (OTCQB: LEMIF) (FRA: 7FL) provides an update on its exploration activities in Romania and latest assay results. Key Findings from 2025 CampaignMapping and sampling...

Hexagon Purus ASA’s fourth quarter results 2025 will be released on 10 February 2026, 07:00 CET. Morten Holum (CEO) and Salman Alam (CFO) will present the results at 08:30 CET and the presentation will be broadcasted live via https://hexagonpurus.vivida.live. The presentation will be held in English and will be virtual. A recording of the presentation will be made available on www.hexagonpurus.com. For more information: Mathias Meidell, IR Director, Hexagon Purus ASATelephone: +47 909 82 242 | mathias.meidell@hexagonpurus.com Salman Alam, CFO, Hexagon Purus ASA Telephone: +47 476 12 713 | salman.alam@hexagonpurus.com About Hexagon Purus ASA Hexagon Purus enables zero emission mobility for a cleaner energy future. The company is a world leading provider of hydrogen Type 4 high-pressure cylinders and systems, battery systems and...

N Very strong Q4 2025 at +5.9% Confident in delivering a 7th year of outperformance in 2026 February 3, 2026+5.9% Q4 organic growth, leading to +5.6% in 2025 Solid FY performance across all regions: U.S. at +5.2%, Europe +4.2% and APAC at +5.8% Industry-leading financial KPIs:18.2% operating margin rate, up 20 basis points year-on-year Headline EPS of €7.48, up 6.6% at constant currency Free cash flow1 at €2.0 billion, up 10.6% 2025 proposed dividend at €3.75 per share, up 4.2%, fully paid in cashExpect to outperform again for 7th consecutive year in 2026: Full year organic growth guidance of +4% to +5% Improving best-in-class financial ratios in 2026:Operating margin rate slightly above 18.2% Free cash flow1 at c. €2.1 billion2FY 2025 results  2025 2025 vs 2024Net organic growth3 +5.6%  Operating margin rate 18.2% +20bps  2025 2025...

 Data published in Molecular Psychiatry Ad Hoc Announcement Pursuant to Art. 53 LR  Geneva, Switzerland, February 3, 2026 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today publication of data in Molecular Psychiatry1 demonstrating that targeting metabotropic glutamate receptor 7 (mGlu7) with negative allosteric modulators (NAM) could be transformative in the treatment of anxiety and fear-related disorders, such as post-traumatic stress disorder (PTSD). In the study, scientists from the Center for Psychiatric Neurosciences (CNP, CHUV/UNIL) in Lausanne, Switzerland, evaluated the effects of ADX71743, a highly selective mGlu7 NAM, in established models of fear learning...